Total Cholesterol and APOE-Related Risk for Alzheimer's Disease in the Alzheimer's Disease Neuroimaging Initiative

被引:10
|
作者
Dunk, Michelle M. [1 ]
Driscoll, Ira [1 ]
机构
[1] Univ Wisconsin, Dept Psychol, 302 Garland Hall,2441 E Hartford Ave, Milwaukee, WI 53211 USA
基金
美国国家卫生研究院; 加拿大健康研究院;
关键词
Alzheimer's disease; apolipoprotein E4; cholesterol; dementia; lipid metabolism; APOLIPOPROTEIN-E POLYMORPHISM; LOW-DENSITY-LIPOPROTEIN; E EPSILON-4 ALLELE; CARDIOVASCULAR RISK; MENDELIAN RANDOMIZATION; SERUM-CHOLESTEROL; LIFE; DEMENTIA; DIETARY; METAANALYSIS;
D O I
10.3233/JAD-215091
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background: APOE epsilon 4 allele confers greatest genetic risk for Alzheimer's disease (AD), yet mechanisms underlying this risk remain elusive. APOE is involved in lipid metabolism, and literature suggest relationships between high total cholesterol, APOE, and AD. Further investigation is needed to elucidate the potential role of total cholesterol in AD risk. Objective: To investigate the relationship between total cholesterol and APOE-related AD risk in the Alzheimer's Disease Neuroimaging Initiative. Methods: Participants (N = 1,534) were classified as controls (cognitively normal; N = 404), early mild cognitive impairment (MCI; N = 294), late MCI (N = 539), or AD (N = 297). Total cholesterol levels were compared across APOE genotype and diagnosis. Mendelian randomization was performed to examine causality between total cholesterol and AD risk using APOE as a genetic instrument. Results: Total cholesterol was higher in APOE4+ compared to APOE3 and APOE2+ (ps < 0.04) carriers. Those with AD and late MCI (ps <0.001) had higher total cholesterol than the control group. Comparing APOE4+ to APOE3 carriers, the predicted odds ratios per mg/dL greater total cholesterol were 1.11 for MCI (95% confidence interval, 1.04-7.32), 1.05 for early MCI (1.01-3.22), 1.13 for late MCI (1.05-11.70), 1.21 for AD (1.09-54.05), and 1.13 for composite dementia (MCI or AD; 1.06-11.59) (ps < 0.05, F-statistics > 10). Conclusion: Higher total cholesterol may be a significant contributor to AD risk, particularly in APOE4 carriers who, based on existing literature, tend to have impaired cholesterol metabolism. Our findings highlight a possible mechanism by which APOE confers AD risk and indicate potential for AD risk modification through maintenance of healthy total cholesterol levels.
引用
收藏
页码:1519 / 1528
页数:10
相关论文
共 50 条
  • [21] Cholesterol and risk for Alzheimer's disease
    Kivipelto, M
    [J]. NEUROBIOLOGY OF AGING, 2004, 25 : S6 - S6
  • [22] APOE and Alzheimer's Disease: Neuroimaging of Metabolic and Cerebrovascular Dysfunction
    Brandon, Jason A.
    Farmer, Brandon C.
    Williams, Holden C.
    Johnson, Lance A.
    [J]. FRONTIERS IN AGING NEUROSCIENCE, 2018, 10
  • [23] Biomarkers of Alzheimer's disease in Black and/or African American Alzheimer's Disease Neuroimaging Initiative (ADNI) participants
    Groechel, Renee C.
    Tripodis, Yorghos
    Alosco, Michael L.
    Mez, Jesse
    Qiu, Wei Qiao
    Goldstein, Lee
    Budson, Andrew E.
    Kowall, Neil W.
    Shaw, Leslie M.
    Weiner, Michael
    Jack, Clifford R., Jr.
    Killiany, R. J.
    [J]. NEUROBIOLOGY OF AGING, 2023, 131 : 144 - 152
  • [24] Progression of Alzheimer's Disease by Self-Reported Cancer History in the Alzheimer's Disease Neuroimaging Initiative
    Fowler, Mackenzie E.
    Triebel, Kristen L.
    Cutter, Gary R.
    Schneider, Lon S.
    Kennedy, Richard E.
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2020, 76 (02) : 691 - 701
  • [25] Vascular Risk Factors and Cardiovascular Outcomes in the Alzheimer's Disease Neuroimaging Initiative
    Epstein, Noam U.
    Xie, Hui
    Ruland, Sean D.
    Pandey, Dilip K.
    [J]. AMERICAN JOURNAL OF ALZHEIMERS DISEASE AND OTHER DEMENTIAS, 2012, 27 (04): : 275 - 279
  • [26] Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease
    Veitch, Dallas P.
    Weiner, Michael W.
    Aisen, Paul S.
    Beckett, Laurel A.
    DeCarli, Charles
    Green, Robert C.
    Harvey, Danielle
    Jack, Clifford R., Jr.
    Jagust, William
    Landau, Susan M.
    Morris, John C.
    Okonkwo, Ozioma
    Perrin, Richard J.
    Petersen, Ronald C.
    Rivera-Mindt, Monica
    Saykin, Andrew J.
    Shaw, Leslie M.
    Toga, Arthur W.
    Tosun, Duygu
    Trojanowski, John Q.
    [J]. ALZHEIMERS & DEMENTIA, 2022, 18 (04) : 824 - 857
  • [27] Biomarkers and phenotypic expression in Alzheimer's disease: exploring the contribution of frailty in the Alzheimer's Disease Neuroimaging Initiative
    Canevelli, Marco
    Arisi, Ivan
    Bacigalupo, Ilaria
    Arighi, Andrea
    Galimberti, Daniela
    Vanacore, Nicola
    D'Onofrio, Mara
    Cesari, Matteo
    Bruno, Giuseppe
    [J]. GEROSCIENCE, 2021, 43 (02) : 1039 - 1051
  • [28] Clusters of male and female Alzheimer’s disease patients in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) database
    Gamberger D.
    Ženko B.
    Mitelpunkt A.
    Shachar N.
    Lavrač N.
    [J]. Brain Informatics, 2016, 3 (3) : 169 - 179
  • [29] Biomarkers and phenotypic expression in Alzheimer’s disease: exploring the contribution of frailty in the Alzheimer’s Disease Neuroimaging Initiative
    Marco Canevelli
    Ivan Arisi
    Ilaria Bacigalupo
    Andrea Arighi
    Daniela Galimberti
    Nicola Vanacore
    Mara D’Onofrio
    Matteo Cesari
    Giuseppe Bruno
    [J]. GeroScience, 2021, 43 : 1039 - 1051
  • [30] Differential atrophy along the longitudinal hippocampal axis in Alzheimer's disease for the Alzheimer's Disease Neuroimaging Initiative
    Morais-Ribeiro, Rafaela
    Almeida, Francisco C.
    Coelho, Ana
    Oliveira, Tiago Gil
    [J]. EUROPEAN JOURNAL OF NEUROSCIENCE, 2024, 59 (12) : 3376 - 3388